LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- PhorMed Inc. (PhorMed or Company) recently filed a Form C for the purpose of launching a Regulatory CF, equity crowdfunding campaign, on the platform WeFunder at https://wefunder.com/phormed.
With a successful raise, the Company's goal is to enroll patients in phase II studies for ARDS and HL, and in parallel the Company intends to continue its on-going preclinical research in PD and ARDS. If additional capital is raised beyond the $5 million, the Company's plan is to launch its phase II study in AMLAML.
The Company has successfully raised $3.5 Million to date. $2.75 million was from two previous equity crowdfunding campaigns from 4100 plus investors while generating over 8800 followers, on the StartEngine platform. The Company also raised $750,000 from an Angel investors.